Latest P53 Stories
LEXINGTON, Ky., Oct. 13 /PRNewswire/ -- Transposagen Biopharmaceuticals, Inc.
New hypothesis in the FASEB Journal suggests balance between NF-kB and p53 signaling is a promising target for new drugs.
Australian and American scientists have found a way of shrinking tumours in certain cancers â€“ a finding that provides hope for new treatments.
St. Jude Children's Research Hospital scientists discovered a new mechanism cells use to maximize production of a key protein following DNA damage and demonstrated the potential of small molecules to regulate the process and protect healthy tissue.
OMAHA, Neb., Sept. 13 /PRNewswire/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced that it completed the requirements for CE IVD labeling and has significantly expanded distribution of its SURVEYORÂ® Scan K-RAS mutation detection kit throughout most of the European Union.
SAN DIEGO, Sept. 2 /PRNewswire/ -- LifeVantage Corporation (OTC Bulletin Board: LFVN), the maker of ProtandimÂ®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving ProtandimÂ® was published in the scientific journal PLoS ONE.
Study suggests potential for new oncolytic therapies.
Researchers at Beth Israel Deaconess Medical Center (BIDMC) have uncovered the genes that regulate MDM2, an oncogene that, in turn, regulates the tumor suppressor protein p53.
New research by scientists at Cold Spring Harbor Laboratory (CSHL) has illuminated in fine detail one of the genetic paths that leads to a particularly aggressive form of leukemia.
Identification of a key player in a signaling pathway involved in the development of melanoma â€“ the deadliest form of skin cancer â€“ may offer hope for new targeted melanoma therapies.